Nina Webster

Nina Webster is the CEO and Managing Director of Dimerix Limited (ASX: DXB), an Australian clinical-stage biopharmaceutical company. Her career is firmly in life sciences — drug development, clinical trials, and commercial licensing — with no direct connection to mining, metals, or energy resources. Resource investors encountering her name should understand she operates in the healthcare sector, not the commodity space.

Webster holds a PhD and has over thirty years of experience in product development and intellectual property strategy. Before leading Dimerix, she spent a decade as Director of Business Development at Acrux Ltd (2001–2011), an Australian transdermal drug delivery company. She has also served as a Non-Executive Director at Linear Clinical Research Ltd. Her expertise centers on advancing drug candidates through regulatory pathways and structuring commercial partnerships — not evaluating mineral deposits or resource projects.

Under her leadership, Dimerix is advancing DMX-200, a treatment for FSGS (Focal Segmental Glomerulosclerosis, a rare kidney disease), through a Phase 3 global clinical trial. The company has secured licensing deals collectively valued at approximately A$1.4 billion, reflecting the commercial potential of its kidney disease pipeline. These achievements are meaningful in biotech investing but do not translate to commodity market relevance.

For mining and commodity investors, Webster's commentary and Dimerix's progress offer no direct applicability. Those researching her should approach from a healthcare investment angle rather than a resource investment perspective.